Research programme : antibody based therapeutics - INGENIA Therapeutics
Latest Information Update: 03 Nov 2023
At a glance
- Originator INGENIA Therapeutics
- Class Anti-inflammatories; Antibodies
- Mechanism of Action TIE-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammation; Unspecified
Most Recent Events
- 20 Oct 2023 Research programme: therapeutics - INGENIA Therapeutics is available for licensing as of 20 Oct 2023. https://www.ingeniatx.com/en/sub/technology/pipeline.php
- 20 Oct 2023 Preclinical trials in Inflammation in USA (Parenteral) (INGENIA Therapeutics pipeline, October 2023)
- 20 Oct 2023 Preclinical trials in Unspecified in USA (Parenteral) (INGENIA Therapeutics pipeline, October 2023)